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Background:  Sleep  disordered  breathing  (SDB)  is highly  prevalent  in  patients  with  cardiovascular  disease,
although  it  is  not  clear  whether  SDB  has  any  link  to coronary  atherosclerotic  burden  in patients  with
stable  coronary  artery  disease  (CAD).  This study  sought  to  analyze  the  links  between  SDB,  coronary
atherosclerotic  burden,  and cardiac  biomarkers  in  stable  CAD  patients.
Methods  and  results:  We  studied  83 consecutive  patients  who  underwent  coronary  angiography  or
scheduled  percutaneous  coronary  intervention.  SDB  was  evaluated  by an  ambulatory  polysomno-
graphic  monitoring  device.  Coronary  atherosclerotic  burden  was  evaluated  by the  Gensini  score,
and  myocardial  stress/injury  were  assessed  by measuring  plasma  levels  of N-terminal  pro-B-type
natriuretic  peptide  (NT-proBNP)  and  high  sensitivity  troponin  T (hs-TnT).  Patients  with  an  apnea
hypopnea  index  (AHI)   15  events/h  (n =  32)  showed  signiﬁcantly  higher  Gensini  score  (35.7  ± 38.0  vs
20.1  ± 19.7,  p  =  0.033)  than  those  with  AHI  < 15.  The  higher  AHI  group  showed  signiﬁcantly  higher  NT-
proBNP  (275.8  ±  402.6  pg/ml  vs  131.9  ±  146.3  pg/ml,  p  = 0.047)  and  hs-TnT  levels  (0.011  ± 0.005  ng/ml  vs
0.008  ± 0.003  ng/ml,  p =  0.015).  Furthermore  it was  revealed  that  AHI  signiﬁcantly  correlated  with  the
Gensini  score  (r  = 0.253,  p =  0.036),  NT-proBNP  (r = 0.266,  p = 0.027),  and  hs-TnT  (r = 0.274,  p =  0.023),  and
multiple  stepwise  linear  regression  analysis  revealed  that  AHI  (  =  0.257,  p = 0.029)  and  history  of  smoking
(  =  0.244,  p =  0.038)  were  independently  correlated  with  Gensini  score  among  clinical  and  SDB-related
parameters.
Conclusions:  Severity  of  SDB  has  a signiﬁcant  link  to  the  severity  of  coronary  atherosclerotic  burden,  which
also  reﬂected  elevated  NT-proBNP  and  hs-TnT  as  silent  myocardial  ischemia  and  minute  myocardial
injury  even  in stable  CAD  patients.
2  Jap© 201
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Sleep disordered breathing (SDB) has a higher prevalence in the
opulation with cardiovascular disease, which seems to link to the
athophysiology of the disease. The prevalence of SDB, deﬁned as
n apnea-hypopnea index (AHI) of 5 or higher, has been estimated
t 24% for men  and 9% for women in the general population [1].
DB has a major impact on patients with systemic hypertension,
oronary artery disease (CAD), atrial ﬁbrillation, etc. [2].
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Obstructive sleep apnea (OSA), which is frequently observed
among SDB, is characterized by periodic intermittent hypoxia
followed by partial and complete pharyngeal collapse and ces-
sation of breathing occurring during sleep. OSA leads to periodic
intermittent hypoxia, exacerbation of negative intrathoracic pres-
sure, and arousal, which leads to cardiovascular quiescence during
non-rapid eye movement sleep to the storm condition by acti-
vating a cascade of hemodynamic, autonomic, inﬂammatory, and
metabolic effects. The cycles of intermittent hypoxia and carbon-
dioxide retention derange the balance between sympathetic and
parasympathetic nervous regulation. This imbalance raises the
heart rate with predominant sympathetic tone and systemic blood
pressure (BP) with sympathetically mediated peripheral vasocon-
striction [3].  Intermittent hypoxia activates inﬂammation, which
impairs vascular endothelial function, and elevated inﬂammatory
biomarkers, such as C-reactive protein [4] and oxidative stress
vier Ltd. All rights reserved.
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5] play an important role in the pathogenesis and progression of
therosclerosis among CAD patients. OSA results in repetitive noc-
urnal hypoxia and sleep disturbance, which induces an increase
n cytokine and inﬂammatory markers. Several studies [6–8] have
hown that SDB is more prevalent in CAD patients and that it
ould provoke cardiovascular events. It has thus emerged as an
ndependent risk factor in patients with CAD. However, there
ave been few reports investigating the impact of SDB on the
everity of atherosclerotic plaque burden and cardiac biomark-
rs reﬂecting myocardial stress or injury in patients with stable
AD.
ethods
tudy population
We  conducted a cross-sectional, single-observational study.
his study consisted of 83 consecutive (66 ± 11 years, male 87%)
atients who were referred to the Nippon Medical School Chiba-
okusoh Hospital for the evaluation and treatment of CAD.
ll patients underwent coronary angiography (CAG) or sched-
led percutaneous coronary intervention (PCI) from September
o December 2008. They attended sleep polygraphic monitor-
ng for one night within one week before CAG or PCI. Major
linical exclusion criteria included signiﬁcant renal dysfunction
creatinine ≥2 mg/dl), prior acute coronary syndrome or coronary
rtery bypass graft within the previous one month, symptomatic
eart failure (≥New York Heart Association class II) within the
revious two weeks, severe valvular heart disease, cardiomyopa-
hy, severe respiratory diseases with required oxygen inhalation.
he study was approved by the Institutional Human Subjects
eview Committee at Nippon Medical School Chiba-Hokusoh
ospital. Informed written consent was obtained from all partici-
ants.
nalysis of sleep apnea
The presence and severity of sleep apnea were determined by an
vernight ambulatory cardiorespiratory monitoring device (Somté,
ompumedics, Abbotsford, Victoria, Australia). Available signals
nclude electrocardiograms, nasal airﬂow, thoracic and abdominal
ffort by breathing, percutaneous oxygen saturation (SpO2), and
ulse rate as previously reported [9–11]. Thoracoabdominal move-
ents were recorded by respiratory inductance plethysmography.
s the respiratory sensor, a thermistor was used to detect oronasal
ignals. SpO2 was recorded by digital pulse oximetry (sampling
requency of 1 s). The oximeter signal quality of the cardiorespi-
atory monitoring device was proven to be valid in comparison
ith polysomnography [9,10].  All obtained signal data were man-
ally analyzed with the following criteria to detect apnea and
ypoxia. Apnea was deﬁned as complete cessation of airﬂow for
ore than 10 s. Hypopnea was deﬁned as a reduction of ≥50% in
idal volume from baseline for more than 10 s with oxygen desat-
ration of 4% from baseline [12]. The AHI (apnea-hypopnea index)
as deﬁned as the total number of apnea and hypopnea episodes
er hour during sleep. The oxygen desaturation index (ODI) was
he number of times per hour of sleep that the oxyhemoglobin
aturation fell by ≥3%. OSA was diagnosed if complete cessation
f oronasal ﬂow occurred in the presence of thoracoabdominal
reathing movements. We  also analyzed the following data from
he records, baseline SpO2, lowest SpO2, the longest apnea time,
verage heart rate during sleep, cumulative percentage time to total
leep time (%TST) at a pulse-oximetric oxygen saturation below 90%
%SpO2 < 90%).logy 60 (2012) 180–186 181
Coronary angiography and GENSINI score
CAG was performed according to standard techniques. Lumen
narrowing <75% was considered as “non-signiﬁcant CAD” and ≥75%
as a signiﬁcant stenosis. The coronary atherosclerotic burden was
evaluated by coronary disease severity score based on a Gensini
score method [13]. This score was  developed with points assigned
according to the category of severity of the stenosis (0 for 0–24%,
1 for 25–49%, 2 for 50–74%, 4 for 75–89%, 8 for 90–98%, 16 for
99%, and 32 for 100%) adjusting for lesion location, with more
proximal lesions receiving a higher weighting factor. The Gensini
score equals the sum of all segment scores. Each segment score
equals the segment weighting factor multiplied by the severity
score.
Measurement of hs-CRP, NT-proBNP and hs-TnT
Blood samples were drawn with an indwelling intra-artery
catheter immediately before CAG or PCI. Blood samples were drawn
in vacuum tubes containing lithium heparin, centrifuged, and the
plasma was stored at −70 ◦C for later measurements. The high-
sensitivity C-reactive protein (hs-CRP) levels were measured with
a latex turbidimetric immunoassay (Siemens Healthcare Diagnos-
tics, Tarrytown, NY, USA). The N-terminal pro-B-type natriuretic
peptide (NT-proBNP) levels were determined with the use of a
two-site electrochemiluminescence immunoassay (ECLIA, Roche
Diagnostics Ltd., Rotkreuz, Switzerland). High sensitivity troponin T
(hs-TnT) measurements were performed in the research laboratory
of Roche Diagnostics in Japan, using an electrochemilumines-
cence immunoassay (precommercial assay, Roche Diagnostics Ltd,
Rotkreuz, Switzerland). This assay had an analytical range from
0.003 to 10 ng/ml, the 99th percentile value of 0.0135 ng/ml and
the Coefﬁcient Variance of 9% by using the Elecsys® (Roche)
[14].
Statistical analysis
Statistical analysis was performed using the SPSS statistical soft-
ware package, version 14.0 (SPSS Inc., Chicago, IL, USA). Discrete
variables are presented as counts and percentages. Continuous vari-
ables are presented as the means ± SD, as appropriate. Because
hs-CRP levels have a skewed distribution, logarithmically trans-
formed hs-CRP values were used in analyzing data. Comparisons
between the two  AHI groups were performed by the unpaired
Student’s t-test. The 2 or Fisher’s exact test was used to com-
pare nominal variables. To analyze the correlation between SDB
parameters, the Gensini score, and biomarkers, Pearson correlation
coefﬁcients were calculated. Statistical signiﬁcance was assumed at
a p-value of <0.05. We deﬁned the stepwise linear regression with
explanatory variables which included age, sex, body mass index,
systolic BP, left ventricular ejection fraction (LVEF), AHI, heart rate
during sleep, history of smoking, estimated glomerular ﬁltration
rate (eGFR), low-density lipoprotein/high-density lipoprotein ratio,
glycated hemoglobin A1c, log transformed hs-CRP as the model 1.
In the model 2, Gensini score was  added to the explanatory vari-
ables. The stepwise multiple linear regression analysis with model
1 was  used to examine the independent association of the AHI levels
with Gensini score. The stepwise multiple linear regression analy-
ses with models 1 and 2 were used to examine and to reveal the
independent interaction of AHI and Gensini score with the eleva-
tion of NT-proBNP and hs-TnT, respectively.
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83 Consecutive patients who underwent CAG or PCI 
and polygraphic monitoring
Heart failure
in two weeeks
n  = 2
Excluded 
CABG in one month
n  = 3
( n = 14)
Myocardial infarction
in one month
n = 7
Stable CAD
Severe Aortic 
valve stenosis
n = 1
n = 69
Cardiomyopathy
n = 1
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Aig. 1. Flow chart detailing number of all enrolled patients, excluded patients, and
xcluded from total 83 patients. CAG, coronary angiography; PCI, percutaneous cor
esults
atient backgroundsA ﬂow diagram detailing the number of patients undergoing
he full set of CAG, polygraphic analysis, and analysis of cardiac
iomarkers is presented in Fig. 1. We  ﬁnally analyzed 69 patients
able 1
emographic and cardiovascular biomarkers in 69 coronary artery disease patients.
Total AHI <
n 69 37 
Age,  years 66 ± 11 65 ±
Male,  n (%) 55 (80) 28 (7
Abdominal circumference, cm 90 ± 9 88 ±
Body  mass index, kg/m2 24.5 ± 3.5 23.7 
Systolic blood pressure, mmHg 126 ± 16 125 ±
Diastolic blood pressure, mmHg  68 ± 10 69 ±
Heart  rate, beats/min during sleep 60 ± 10 58 ±
GENSINI Score 27.3 ± 30.4 20.1 
LVEF,  % 65 ± 11 67 ±
Prior  myocardial infarction, n (%) 27 (39) 13 (3
Familial history, n (%) 23 (33) 12 (3
History of hypertension, n (%) 47 (68) 25 (6
History of diabetes, n (%) 27 (39) 11 (3
History of hyperlipidemia, n (%) 60 (87) 33 (8
History of smoking, n (%) 51 (74) 27 (7
Lipid  proﬁle
LDL-C, mg/dl 98 ± 25 93 ±
HDL-C, mg/dl 48 ± 11 46 ±
Non-HDL, mg/dl 125 ± 30 119 ±
LDL/HDL ratio 2.1 ± 0.7 2.1 ±
Renal proﬁle
eGFR, ml/min/1.73 m2 70.5 ± 16.8 71.2 
Urine albumin creatinine ratio 42.2 ± 133.7 19.9 
Diabetes proﬁle
Fasting blood sugar, mg/dl 101 ± 19 99 ±
HbA1c, % 5.8 ± 0.9 5.7 ±
Biomarkers
hs-CRP, ng/mla 650.9 ± 3.6 537.0
NT-proBNP, pg/ml 198.7 ± 300.7 131.9
hs-TnT, ng/ml 0.009 ± 0.004 0.008
NT-proBNP  1000 pg/ml, n (%) 4 (6) 0 (0)
hsTnT  0.014 ng/ml, n (%) 7 (10) 1 (3)
alues are mean ± SD or number of patients (%).
-value shows the statistical signiﬁcance between the below 15 and greater than equal to
VEF, left ventricular ejection fraction; HDL, high-density lipoprotein; LDL, low-density lip
HI,  apnea-hypopnea index; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-t
a Values are geometrized mean ± SD.e CAD patients. A total of 69 patients were ﬁnally analyzed after 14 patients were
 intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease.
with stable CAD after exclusion from 83 patients. The baseline char-
acteristics of patients who  completed polygraphic monitoring are
shown in Table 1. The parameters of the sleep study in the stud-
ied patients showed that the mean AHI was  18.0 ± 11.9 events/h,
the mean 3% ODI was  18.7 ± 12.4 events/h, and the mean mini-
mum  SpO2 was 84.3 ± 7.7% (Table 2). The prevalence of AHI less
than 5 was  9%, 5 ≤ AHI < 15 was  45%, 15 ≤ AHI < 30 was 27%, and
 15 (events/h) AHI  15 (events/h) p-value
32
 11 67 ± 11 0.310
6) 27 (84) 0.550
 9 93 ± 7 0.019
± 3.8 25.5 ± 3.0 0.033
 15 128 ± 17 0.495
 10 68 ± 11 0.708
 9 62 ± 10 0.047
± 19.7 35.7 ± 38.0 0.033
 9 63 ± 13 0.105
5) 14 (44) 0.621
2) 11 (34) 0.533
8) 22 (69) 0.562
0) 16 (50) 0.070
9) 27 (84) 0.406
3) 24 (75) 0.535
 23 103 ± 26 0.108
 9 50 ± 12 0.233
 28 132 ± 30 0.068
 0.7 2.2 ± 0.8 0.549
± 13.9 69.7 ± 19.8 0.723
± 34.0 69.9 ± 194.9 0.136
 16 105 ± 22 0.168
 0.8 5.9 ± 0.9 0.364
±3.9 813.5 ± 3.2 0.180
 ± 146.3 275.8 ± 402.6 0.047
 ± 0.003 0.011 ± 0.005 0.015
 4 (13) 0.042
 6 (19) 0.044
 15 of AHI.
oprotein; eGFR, estimated glomerular ﬁltration rate; HbA1c, glycated hemoglobin;
erminal pro-B-type natriuretic peptide; hsTnT, high sensitivity troponin T.
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Table  2
Sleep disordered breathing-related parameters in 69 coronary artery disease patients.
Total AHI < 15 (events/h) AHI  15 (events/h) p-value
n 69 37 32
AHI,  events/h 18.0 ± 11.9 9.1 ± 3.5 28.3 ± 9.5 <0.001
Apnea index, events/h 7.6 ± 8.3 3.0 ± 2.8 12.9 ± 9.5 <0.001
Obstructive apnea index, events/h 6.9 ± 7.4 2.1 ± 2.4 10.3 ± 8.9 <0.001
Central apnea index, events/h 1.6 ± 2.2 0.8 ± 1.0 2.6 ± 2.8 0.001
Percent of obstructive apnea, % 72 ± 27 68 ± 28 75 ± 24 0.344
3%  ODI, events/h 18.7 ± 12.4 10.8 ± 6.7 27.8 ± 11.2 <0.001
4%  ODI, events/h 11.9 ± 10.0 5.8 ± 4.8 18.9 ± 9.8 <0.001
Longest obstructive apnea time, s 42 ± 28 33 ± 23 53 ± 28 0.001
Longest central apnea time, s 19 ± 11 15 ± 11 24 ± 11 0.001
Baseline SpO2, % 96.0 ± 1.4 96.3 ± 1.2 95.6 ± 1.5 0.044
Minimum SpO2, % 84.3 ± 7.7 88.0 ± 3.2 79.9 ± 9.0 <0.001
SpO2 < 90%, % TST 2 ± 5 0.3 ± 0.5 4 ± 7 0.002
Values are mean ± SD.
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t-value shows the statistical signiﬁcance between the below 15 and greater than eq
pm, beats per minute; AHI, apnea-hypopnea index; ODI, oxygen desaturation inde
TST, cumulative percentage time to total sleep time.
reater than or equal to 30 was 19% of the patients. Thus, in stable
AD patients, moderate to severe SDB prevalence was as high as
pproximately 50%.
omparison of patients using an AHI of 15 as the cut-off
We divided the 69 patients into two groups, those with no
r mild SDB (AHI < 15) and those with moderate to severe SDB
AHI ≥ 15). AHI ≥ 15 was deﬁned as the cut-off value by the Ameri-
an Academy of Sleep Medicine [15]. Patients with AHI ≥ 15 (n = 32)
howed signiﬁcantly larger abdominal circumﬂex (93 ± 7 cm vs
8 ± 9 cm,  p = 0.019) and higher body mass index (25.5 ± 3.0 kg/m2
s 23.7 ± 3.8 kg/m2, p = 0.033) compared with those in the lower
HI group. The average heart rate during sleep was  signiﬁ-
antly higher in the higher AHI group (62 ± 10 bpm vs 58 ± 9 bpm,
 = 0.047). In the coronary angiographic analysis, patients with
HI ≥ 15 showed signiﬁcantly higher Gensini score compared with
he lower AHI group (35.7 ± 38.0 vs 20.1 ± 19.7, p = 0.033). However
he prevalence of hypertension, diabetes mellitus, and dyslipidemia
ere not signiﬁcantly different in the two groups. Regarding the
nﬂammatory and cardiac biomarkers, the levels of NT-proBNP and
s-TnT were signiﬁcantly higher in the higher AHI group compared
ith the lower AHI group, however hs-CRP was not signiﬁcantly
ig. 2. Graphs showing correlations between sleep apnea parameters, Gensini score, and
nd  Gensini score, NT-proBNP, hs-TnT, and average heart rate during sleep. The upper gr
ime  of apnea and hypopnea. AHI, apnea-hypopnea index; NT-proBNP, N-terminal pro-B- 15 of AHI.
2, percutaneous oxygen saturation.
different in the two  groups. The proportion of patients with NT-
proBNP levels 1000 pg/ml was  signiﬁcantly larger in the higher
AHI group (0%.vs 13%, p = 0.042). Also the proportion of hs-TnT
0.014 ng/ml was  signiﬁcantly larger in the higher AHI  group (3%
vs 19%, p = 0.044) (Table 1). Thus, patients with moderate to severe
SDB (AHI ≥ 15) suffered from more severe coronary atherosclerotic
burden and also more myocardial stress and injury, independent
of conventional risk factors such as age, gender, hypertension, dia-
betes mellitus, dyslipidemia, or smoking status.
Correlations between SDB parameters, severity of CAD and
cardiac biomarkers
We investigated the relationship between SDB parameters and
the severity of CAD assessed by the Gensini score and cardiac
biomarkers. Across all patients, we  found signiﬁcant positive cor-
relations between AHI and Gensini score (r = 0.253, p = 0.036),
NT-proBNP (r = 0.266, p = 0.027), hs-TnT (r = 0.274, p = 0.023), and
the average heart rate during sleep (r = 0.291, p = 0.015). The sum
total time of apnea and hypopnea signiﬁcantly correlated with
Gensini score (r = 0.244, p = 0.043), NT-proBNP (r = 0.283, p = 0.019),
hs-TnT (r = 0.328, p = 0.006), and the average heart rate during sleep
(r = 0.241, p = 0.046), respectively (Fig. 2 and Table 3). Regarding
 cardiac biomarkers. Correlations between sleep disordered breathing parameters
aphs regard the apnea-hypopnea index and the lower graphs regard the sum total
type natriuretic peptide; hs-TnT, high sensitivity troponin T; HR, heart rate.
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Table  3
Correlations between sleep disordered breathing-related parameters, Gensini score, and biomarkers.
Gensini score log hs-CRP NT-proBNP hs-TnT HR during sleep
r p-value r p-value r p-value r p-value r p-value
Gensini score – – 0.102 0.404 0.266 0.027 0.349 0.003 0.036 0.771
AHI  0.253 0.036 0.191 0.115 0.266 0.027 0.274 0.023 0.291 0.015
The  sum total time of apnea and hypopnea 0.244 0.043 0.174 0.152 0.283 0.019 0.328 0.006 0.241 0.046
hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro-B-type natriuret
index.
Table  4
Multiple stepwise linear regression analysis to examine independent determinants
of Gensini score among clinical and sleep disordered breathing-related parameters.
Gensini score
ˇ p
Smoking (yes = 1) 0.244 0.038
Apnea-hypopnea index 0.257 0.029
(Model adjusted R2 = 0.097)
Age, sex, body mass index, systolic blood pressure, left ventricular ejection frac-
tion, apnea-hypopnea index, heart rate during sleep, smoking, estimated glomerular
ﬁltration rate, low-density lipoprotein/high-density lipoprotein ratio, hemoglobin
A1c, and log transformed high-sensitivity C-reactive protein were entered as the
e
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sxplanatory variables.
: Standardized regression coefﬁcient.
s-CRP, a signiﬁcant correlation was found with the average heart
ate during sleep (r = 0.280, p = 0.020) among the various parame-
ers of SDB.
A stepwise multiple linear regression analysis revealed AHI and
moking to be independent determinants of Gensini score (Table 4).
emale gender, systolic BP, LVEF, and AHI were selected as the
ndependent determinants of NT-proBNP, and eGFR and AHI were
elected as those of hs-TnT in the model 1. When Gensini score
as added to the explanatory variables, AHI turned out not to be
ndependent and Gensini score was selected as the independent
eterminants of NT-proBNP and hs-TnT in model 2 (Table 5).
iscussionThe prevalence of SDB in patients with cardiovascular disease
s known to be two- or three-fold greater than for populations
ithout cardiovascular disease [16]. The Sleep Heart Health Study
able 5
ultiple stepwise linear regression analysis to examine independent determinants of
arameters.
Model 1a
 ˇ p 
NT-proBNP
Female (yes = 1) 0.386 <0.001 
Systolic BP 0.343 0.001 
LVEF  −0.331 0.001 
AHI  0.211 0.036 
Gensini  score Not included 
(Model adjusted R2 = 0.382) 
High  sensitive troponin T
eGFR −0.401 <0.001 
AHI  0.266 0.016 
Gensini  score Not included 
(Model adjusted R2 = 0.213) 
: Standardized regression coefﬁcient.
T-proBNP, N-terminal pro-B-type natriuretic peptide; BP, blood pressure; LVEF, left ven
ltration rate; BMI, body mass index; LDL/HDL, low-density lipoprotein/high-density lipo
ensitivity troponin T.
a Age, sex, BMI, systolic BP, LVEF, AHI, heart rate during sleep, smoking, eGFR, LDL/HDL r
b Variables used in the Model 1 plus Gensini score were entered as the explanatory varic peptide; hsTnT, high sensitivity troponin T; HR heart rate; AHI, apnea-hypopnea
reported an independent association between SDB with AHI ≥ 11
and CAD and congestive heart failure [17]. The relative odds ratios
were 1.27 and 2.38 respectively. Other studies have also revealed
a signiﬁcant link between severity of SDB and increased car-
diovascular morbidity and mortality [6,18],  however no studies
have yet shown a detailed relationship between the severity of
SDB and severity of coronary atherosclerotic burden based on
CAG ﬁndings nor novel sensitive cardiac biomarkers in stable
CAD patients.
Linkage between SDB and coronary atherosclerotic burden
In the present study, we divided the patients into two  groups
according to a cut-off AHI value of 15, namely non to mild SDB
and moderate to severe SDB. We  could not ﬁnd any signiﬁcant
differences between the two  groups with regard to conventional
coronary risk factors; family history, hypertension, diabetes mel-
litus, lipid proﬁle, or smoking. The lack of differences among
the coronary risk factors between the two  groups suggested that
severity of SDB would contribute to the progression of coronary
atherosclerosis independently, in addition to conventional coro-
nary risk factors. The multiple linear regression analysis showed
AHI to be independently associated with Gensini score and the
positive correlations between the Gensini score and both AHI and
sum total time of apnea and hypopnea. These ﬁndings proved
that the severity of SDB signiﬁcantly inﬂuenced the progression
of the atherosclerotic burden. Intermittent hypoxia induced by SDB
would accelerate the progression of atherosclerotic burden through
many possible mechanisms, such as activation of sympathetic
nerve activity, increasing inﬂammatory cytokines and oxidative
stress [19]. Ryan et al. showed a preferential activation of inﬂamma-
tory pathways mediated by the transcription factor nuclear factor
 NT-proBNP and hs-TnT among clinical and sleep disordered breathing-related
Model 2b
 ˇ p
0.388 <0.001
0.362 <0.001
−0.316 0.002
– –
0.230 0.022
(Model adjusted R2 = 0.390)
−0.392 <0.001
– –
0.332 0.002
(Model adjusted R2 = 0.253)
tricular ejection fraction; AHI, apnea-hypopnea index; eGFR, estimated glomerular
protein; Hb, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high
atio, HbA1c, and log transformed hs-CRP were entered as the explanatory variables.
iables.
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appa B (NF-B) over adaptive hypoxia-inducible factor-1 (HIF-1)
dependent pathways in a cell culture model of intermittent
ypoxia [20]. Intermittent hypoxia and reoxygenation in SDB
ith activation of NF-B leads to the production of various pro-
nﬂammatory mediators, such as tumor necrosis factor alfa, inter-
eukin (IL)-6 or IL-8 which mediate the interaction of inﬂammation
nd endothelial dysfunction [21]. Hypoxemia mediated by inter-
ittent apnea plays an important role in the inﬂammation cascade.
Secondary hypertension associated with SDB would be also
nvolved in inducing the pathophysiological mechanisms. Elevated
P accompanied with SDB and intermittent hypoxia, activates
hemoreceptors and the sympathetic nervous system [22] to
nduce endothelial dysfunction, arterial atherosclerosis, and artery
emodeling. SDB predominantly increases BP during sleep, result-
ng in the non-dipping pattern or riser pattern of nocturnal BP.
 characteristic ﬁnding of BP in subjects with SDB is increased
octurnal BP variability [23]. Periodic surges in BP, which occur
t the same phase from later periods of apnea to the cessation
f apnea, contribute to the shear stress on the vessels. These BP
urges which occur more frequently would result in artery remod-
ling and elevated arterial stiffness, ﬁnally leading to progression of
therosclerosis. Patients with SDB had an elevated arterial stiffness,
nd Kato et al. reported that short-term continuous positive airway
ressure (CPAP) therapy reduced atrial stiffness, as shown by the
ssociation of a reduction in cardio-ankle vascular index with the
sage of CPAP in patients with moderate to severe SDB [24].
inkage between SDB and cardiac biomarkers
To the best of our knowledge, we are the ﬁrst to report that
ven in stable CAD patients, those with severe SDB showed silent
yocardial stress detected by NT-proBNP and silent myocardial
njury detected by the hs-TnT assay. A multiple stepwise linear
egression analysis in model 2 revealed Gensini score to be inde-
endently associated with the NT-proBNP and hs-TnT levels. This
ndicated more severe atherosclerotic burden was independently
ssociated with silent myocardial stress and minute myocardial
njury in the stable CAD patients with SDB. The stable CAD patients
ith moderate and severe SDB showed signiﬁcantly higher levels
f NT-proBNP and larger percentage of NT-proBNP 1000 pg/ml
hich had highly provable chronic heart failure in stage C and
 with new classiﬁcation of chronic heart failure updated in
005 [25]. Emdin et al. reported that NT-proBNP concentrations
ncreased from heart failure stage A to D by 107-fold [26]. The
resent study also revealed signiﬁcant correlations between AHI
nd NT-proBNP. These ﬁndings would reﬂect the existence of silent
yocardial ischemia or stress induced by more severe SDB. In
he multiple stepwise linear regression analysis, female gender,
ystolic BP, and LVEF were found to be independent factors of
T-proBNP elevation. It was well known that these factors were
ssociated with SDB [27,28]. In a community-based cohort, SDB
as associated with reduced left ventricular systolic function [29].
hese studies suggested that SDB would have indirect inﬂuence
o the elevation of NT-proBNP and silent myocardial stress in sta-
le CAD patients. The augmented cardiac afterload developed by
ctivated sympathetic activity, the BP surge, and increased nega-
ive intrathoracic pressure would cause myocardial stress and the
levation of NT-proBNP.
It has also been found that patients with moderate and severe
DB showed signiﬁcantly higher levels of hs-TnT compared with
hose with non and mild SDB. Furthermore they had a larger
ercentage of hs-TnT 0.014 ng/ml which is the 99th percentile
oncentration of this hs-TnT assay [14] with cut-off value of newly
eveloped classiﬁcation for the universal deﬁnition of myocardial
nfarction [30]. In the multiple stepwise linear regression analysis,
ensini score and eGFR were found to be independent factors oflogy 60 (2012) 180–186 185
hs-TnT. Our data suggested the presence of silent minute myocar-
dial injury was evoked by more severe atherosclerotic burden
associated with more severe SDB. Ndrepepa et al. reported that
there was a close association between hs-TnT level and severity of
CAD conﬁrmed by angiographic atherosclerotic burden in patients
with stable CAD [31]. The previous and our present observations
suggest that the hs-TnT measurement enables the identiﬁcation
of subjects who have minute myocardial injury. Although Gami
et al. reported that severe SDB patients with CAD did not show
myocardial injury assessed by conventional cardiac troponin T
assay (detection limit 0.01 ng/ml) [32], which is less sensitive com-
pared with the present hs-TnT assay [33]. The present study applied
a highly sensitive assay for cardiac troponin T permitting mea-
surement of concentrations with an analytical range from 0.003
to 10 ng/ml which is to explain the ability to ﬁnd an associa-
tion between minute myocardial injury and atherosclerotic burden
associated with severity of SDB in the present study. Apart from
physical stress such as hemodynamic changes, periodic hypoxia
followed by rapid reoxygenation might induce myocardial injury
related to ischemia and reperfusion. The regional metabolic effects
of hypoxia lead to intermittent increases in coronary blood ﬂow
during apnea, however in stable CAD patients the limited coronary
ﬂow reserve decreased the oxygen supply during apnea, resulting
in myocardial ischemia. Hamilton et al. reported that the coronary
blood ﬂow reserve mismatched the demand of increased myocar-
dial work [34] and this disturbed ﬂow-metabolic coupling led to
nocturnal myocardial ischemia and injury in stable CAD patients
with SDB. We  revealed that even in stable CAD patients, hs-TnT
had a positive correlation with the AHI and sum total time of
apnea and hypopnea. This supported the fact that the severity of
SDB and nocturnal hypoxia are signiﬁcantly related to the develop-
ment of silent myocardial injury. Supporting this ﬁnding, Milleron
et al. reported that treatment of OSA in CAD patients by CPAP
was associated with a decrease in the occurrence of cardiovas-
cular events [35]. Decreases in the AHI and nocturnal hypoxia
would relieve silent myocardial stress and injury in patients
with severe OSA, and decrease the occurrence of cardiovascular
events.
Clinical implications and study limitations
The present ﬁndings suggest that the severity of SDB sig-
niﬁcantly links to the development of coronary atherosclerotic
burden even in patients with stable CAD, and that silent myocar-
dial stress and injury could be ampliﬁed by the presence of
severe SDB, thus resulting in the elevation of NT-proBNP and hs-
TnT.
In this study we  did not measure nocturnal BP, pro-
inﬂammatory cytokines, or adhesion molecules associated with
inﬂammation to clarify the mechanism in detail. The sample size
in the present study was not large, further study should be needed
to conﬁrm the correlation between coronary atherosclerotic bur-
den, cardiac biomarkers, and SDB-related parameters. Furthermore
investigation remains to be established to demonstrate therapeu-
tic implication of SDB for the primary and secondary prevention of
CAD.
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